|
Back to EZorb Newsletter Index |
|
In this issue:
Letter I: From Lisa S., Glen Rock, NJ Hello: I wanted to write when I felt the VAST Improvement almost immediately- Now it is two months later and I can NOT EVEN BELIEVE that my OH SO PAINFUL DUELING BONE SPURS pain has subsided. To be clear, I drink the magic two inches of drink, which tastes fine, so not a bother, 3X a day, and I rarely if ever experience pain. EVER! What I did happen to notice though is that if I skip a dose, or in the case that an entire day goes by and I forget, the pain is quickly back, not as bad, but it makes me realize that it has to be a part of my daily regimen. So yes it is a cure, but it is an ongoing cure. I would love to work for this company. I think that so many people could find relief from their woes. If you knew the agony I was in, to how I feel now, it's a small miracle. The morning is no longer Dreaded. THANKS SO MUCH! Lisa A S. This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life. Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Arthritis Doesn't Make It Easy For Type 2 Diabetes ControlPatients with rheumatoid arthritis (RA) or osteoarthritis (OA) and comorbid adult-onset type 2 diabetes have a clinical profile of severe diabetes with poor glycemic control, researchers report. These findings are based on an observational study of 167 individuals with type 2 diabetes and either RA (n=118) or osteoarthritis (n=49). The average age was 64 years for people with RA and 70 years for those with osteoarthritis, and approximately three-quarters of individuals in both groups were women. The investigators report in Rheumatology that people in both groups had “suboptimal metabolic control” and a “high frequency of cardiovascular risk factors.” Specifically, average glycated hemoglobin (HbA1c) levels were 7.0% (53 mmol/mol) among people with RA and 7.3% (56 mmol/mol) in those with osteoarthritis; a respective 27.9% and 26.5% required insulin, and the prevalence of complications (neuropathy, retinopathy, and nephropathy) ranged from 8.9% to 19.2%. The mean BMI was 27.7 and 31.8 kg/m2 in the RA and osteoarthritis groups, respectively, and a corresponding 70% and 76% had hypertension. Despite both groups having “similar type 2 diabetes characteristics,” the study authors note that insulin resistance correlated with age and obesity among patients with osteoarthritis, but “related to the joint and systemic inflammatory activity of the disease” in those with RA. People with RA also had a significantly greater degree of insulin resistance than those with osteoarthritis after adjustment for age, BMI, and corticosteroid use, with a HOMA2-IR measure of 1.94 versus 1.10. In a multivariate analysis, having moderate or high RA disease activity - indicated by a DAS28 score above 3.2 points - was significantly associated with decreased insulin sensitivity as indicated by a HOMA2-S measure of less than 42 (odds ratio [OR]=4.46), as was having C-reactive protein levels above 10 mg/L (OR=6.92). “These findings may have therapeutic implications, with the potential targeting of insulin resistance through the treatment of joint and systemic inflammation,” say Jerome Avouac (Universite de Paris, France) and co-authors. The team also evaluated the impact of RA treatment on metabolic indices, finding that the use of tumor necrosis factor inhibitors was significantly associated with insulin sensitivity, but not with glycemic control, suggesting that “further prospective studies are necessary to determine whether this therapeutic class may improve the outcome of type 2 diabetes.” Other RA treatments - including alternative biologics (tocilizumab, abatacept, and rituximab), methotrexate, hydroxychloroquine, and low-dose corticosteroids - were not significantly associated with insulin sensitivity or glycemic control. Original research was published in Rheumatology 2021; doi:10.1093/rheumatology/keaa810. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families
around the world. Click here to read what people say about EZorb
and Marvlix. |
|
Back to EZorb Newsletter Index |